Mitsubishi UFJ Asset Management Co. Ltd. Has $365,000 Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 9.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,942 shares of the medical technology company’s stock after purchasing an additional 3,336 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Alphatec were worth $365,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the company. American Century Companies Inc. increased its position in Alphatec by 36.5% during the 4th quarter. American Century Companies Inc. now owns 4,989,057 shares of the medical technology company’s stock worth $45,800,000 after buying an additional 1,334,780 shares during the period. Emerald Advisers LLC increased its position in Alphatec by 112.4% during the fourth quarter. Emerald Advisers LLC now owns 1,456,033 shares of the medical technology company’s stock worth $13,366,000 after acquiring an additional 770,586 shares during the period. Polar Asset Management Partners Inc. raised its stake in Alphatec by 381.9% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 621,224 shares of the medical technology company’s stock worth $3,454,000 after purchasing an additional 492,324 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Alphatec by 119.3% in the 4th quarter. Bank of New York Mellon Corp now owns 662,239 shares of the medical technology company’s stock valued at $6,079,000 after purchasing an additional 360,258 shares during the period. Finally, Congress Asset Management Co. grew its position in shares of Alphatec by 235.4% during the 4th quarter. Congress Asset Management Co. now owns 434,966 shares of the medical technology company’s stock worth $3,993,000 after purchasing an additional 305,296 shares in the last quarter. Institutional investors own 66.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Barclays boosted their price target on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, January 22nd. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Alphatec in a report on Tuesday, January 14th. Needham & Company LLC restated a “buy” rating and issued a $16.00 price target on shares of Alphatec in a research report on Thursday, February 27th. StockNews.com raised shares of Alphatec from a “sell” rating to a “hold” rating in a research report on Friday, February 28th. Finally, Piper Sandler raised their target price on shares of Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $17.67.

Insider Buying and Selling

In other news, CEO Patrick Miles sold 6,687 shares of Alphatec stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $12.00, for a total transaction of $80,244.00. Following the sale, the chief executive officer now directly owns 5,501,715 shares of the company’s stock, valued at approximately $66,020,580. This trade represents a 0.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP David Sponsel sold 36,256 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $11.42, for a total value of $414,043.52. Following the completion of the transaction, the executive vice president now directly owns 735,074 shares of the company’s stock, valued at $8,394,545.08. This represents a 4.70 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 337,321 shares of company stock worth $3,828,060 in the last 90 days. Insiders own 22.80% of the company’s stock.

Alphatec Stock Down 2.3 %

ATEC stock opened at $10.21 on Friday. The stock has a market capitalization of $1.47 billion, a P/E ratio of -7.98 and a beta of 1.39. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The firm has a 50-day moving average price of $10.76 and a 200-day moving average price of $9.10. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $14.54.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The company had revenue of $176.79 million during the quarter, compared to the consensus estimate of $172.74 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. As a group, equities research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.